We identified potential biomarkers that might predict response to cetuximab- based CRT.

Docetaxel- based CRT regimen is active and tolerable in esophageal cancer.

Based on the superior safety profile, carboplatin and paclitaxel- based CRT regimens are preferred in patients with locally advanced proximal EC.

Conclusions: This study suggests that SNPs within the TS enhancer region affect the tumor response to preoperative 5-FU- based CRT in rectal cancer.

Conclusion: These data suggest that adjuvant concurrent FU- based CRT significantly improves survival after PD for PC when compared with patients not receiving CRT.